Heat shock proteins in cardiovascular disease and the prognostic value of heat shock protein related measurements

A G Pockley, J Frostegård

Are heat shock protein antibodies directly involved in the pathogenesis of cardiovascular disease?

A number of studies, including the article by Birnie and colleagues in this issue of Heart,1 have reported an association between increased concentrations of circulating heat shock protein antibodies and the severity and progression of cardiovascular disease. In addition, we and others have demonstrated that heat shock proteins, which are also present in the peripheral circulation, protect against rather than exacerbate cardiovascular disease.2,3 Are heat shock protein antibodies directly involved in the pathogenesis of cardiovascular disease, given that such antibodies and the proteins against which they are directed are present in the peripheral circulation of apparently normal individuals?

Heat shock or stress proteins are highly conserved molecules that fulfil a range of functions including cytoprotection and the intracellular assembly, stabilisation, folding and translocation of oligomeric proteins.4 Stress proteins are present in all species, and they are categorised into families that are named on the basis of their approximate molecular weight (for example, the 60 kDa Hsp60). Their synthesis can be induced by a range of cellular insults that induce protein unfolding, mis-folding, or aggregation and a flux of newly synthesised non-native proteins; such insults include oxidative and haemodynamic stress, oxidised low density lipoprotein,5 and inflammatory cytokines, all of which are associated with the development of cardiovascular disease.

HEAT SHOCK PROTEIN ANTIBODIES AND CARDIOVASCULAR DISEASE

In addition to their role as molecular chaperones, heat shock proteins are immunodominant molecules, as a consequence of which a significant element of the immune response to pathogenic microorganisms is directed toward heat shock protein peptides that are derived therefrom.6–7 The phylogenetic similarity between microbial and mammalian forms of these molecules (~50–80% identical residues in the case of the 60 kDa family) has prompted the proposition that they could act as harmful autoantigens and that immune responses to heat shock protein epitopes from infectious agents might crossreact with equivalent “self” molecules and thereby establish a link between infection and various autoimmune disease conditions.6–8 The observations that elevated concentrations of antibodies to the 65 kDa mycobacterial heat shock heat shock protein Hsp65 (which is 75% homologous to human Hsp60) are associated with the severity and progression of vascular disease,9–11 and that anti-Hsp65 antibody values predict the five year mortality of patients with carotid atherosclerosis12 and the incidence of cardiovascular events,13 support the proposition that immunity to heat shock proteins also influences the development and progression of cardiovascular disease.14–16 That antibodies to Hsp65 may act in an immunodominant manner via cross-reactivity with Hsp60 expressed on the surface of human endothelial cells after TNF-α or heat treatment, strengthens this proposition and suggests that endothelial injury resulting from such interactions might occur in vivo.17–19

Interest in the relation between circulating antibodies to “self” Hsp60 and cardiovascular disease has also developed, and the article by Birnie and colleagues in this issue of Heart extends previous work from a number of laboratories in this area.20–24 The authors report that patients admitted with acute cardiac chest pain and elevated values of anti-Hsp60 antibodies exhibited an adverse one year prognosis for coronary heart disease (CHD) related death or non-fatal myocardial infarction.20 This finding contrasts with the observations that anti-Hsp60 antibody concentrations do not predict cardiovascular events in adults,21 despite the fact that high concentrations of these antibodies are present in subjects with coronary artery disease (CAD).22 The additional observation by Birnie and colleagues that concentrations of anti-Hsp65 antibodies do not predict CHD related death or non-fatal myocardial infarction,21 combined with a previous report that anti-Hsp65 antibody concentrations are not significantly raised in patients with severe CHD,23 suggests that the relation between raised concentrations of Hsp65 antibodies and cardiovascular disease might not be a universal one.

The lack of a relation between concentrations of antibodies to Hsp60 and Hsp65, despite the sequence homology of Hsp60 and Hsp65 reported by Birnie and colleagues,1 also questions the proposition that crossreactive or autoimmune Hsp60 responses contribute to disease progression, and data from other studies appear to support this. Autoantibodies to Hsp60 and antibodies to Hsp65 in the sera of patients with...
cardiovascular disease exhibit different epitope specificities\(^2^3\) and the concentrations of these antibodies do not correlate.\(^2^4\) In addition, the presence of raised concentrations of antibodies to chlamydial Hsp60, but not concentrations of antibodies to their human or *Escherichia coli* derived counterparts, is independently associated with CHD.\(^2^5\)

It is clear that the literature in this area is varied, and the precise relation between circulating heat shock protein antibodies and the severity and progression of cardiovascular disease remains unclear. The reasons for the differing findings might result, in part at least, from the varied clinical statuses of the patient populations that have been investigated and monitored, as well as differences in the measurements that have been made. Antibodies to Hsp60 and antibodies to Hsp65 in the sera of patients with cardiovascular disease exhibit different complement activating ability,\(^2^6\) and the functional capacity of circulating antibodies might be a more relevant parameter to consider. Concentrations of complement activating antibodies to Hsp60 are raised in children from families that are at a high risk of developing cardiovascular disease, whereas concentrations of total IgG anti-Hsp60 and anti-Hsp65 antibodies are not related to the risk of developing cardiovascular disease.\(^2^7\)

**CIRCULATING HEAT SHOCK PROTEINS AND CARDIOVASCULAR DISEASE**

Another factor which might confound the perceived relation between circulating heat shock protein antibodies and the presence and severity of cardiovascular disease is the co-existence of heat shock proteins in the peripheral circulation, the presence of which has been reported by a number of investigators.\(^2^8\) Circulating heat shock proteins appear to influence the progression of cardiovascular disease as increases in carotid intima–media thicknesses (a measure of cardiovascular disease) in subjects with established hypertension at a four year follow up have been shown to be significantly less prevalent (odds ratio 0.42) in individuals with high values of Hsp70 in their serum at enrolment.\(^2^9\) A similar, albeit non-statistically significant association between Hsp60 concentrations and the progression of cardiovascular disease was also observed (odds ratio 0.6). No relation between increases in carotid intima–media thicknesses and concentrations of anti-Hsp60 and anti-Hsp65 antibodies was observed, thereby further questioning the robustness of the relation between circulating heat shock protein antibodies and the severity and progression of cardiovascular disease. A cross-sectional study which measured serum Hsp70 concentrations in individuals evaluated for CAD by coronary angiography, and found that concentrations are significantly higher in patients without evidence of CAD, supports the proposition that heat shock proteins influence the progression of cardiovascular disease.\(^3^0\)

The mechanism by which circulating Hsp70 influences the progression of cardiovascular disease is currently unclear; however, one possibility is that heat shock proteins interfere with, or in some way influence the activities of, their corresponding antibodies. As might be expected, soluble heat shock protein–heat shock protein antibody immune complexes are present in the peripheral circulation (unpublished observations). These complexes might influence the impact of circulating heat shock protein antibodies on the pathogenesis and progression of cardiovascular disease.

Although immune complexes are typically regarded as being pro-inflammatory activators of the complement system, the interaction of antigen presenting cells with soluble immune complexes reduces their production of the pro-inflammatory cytokine interleukin (IL)-12, enhances their production of the anti-inflammatory cytokine IL-10, and consequently induces an anti-inflammatory (immunoregulatory) adaptive immune T cell response.\(^3^1\) Given that such shifts in the qualitative nature of immune responses can attenuate atherogenesis in a number of experimental model systems,\(^3^2\)\(^-^3^4\) this might be a mechanism via which circulating heat shock protein–heat shock protein immune complexes could influence the progression of cardiovascular disease.

Although the relation between the concentrations of circulating heat shock proteins and cardiovascular disease suggest that these proteins might have some therapeutic potential, this remains to be demonstrated. It is the qualitative nature of the immune response to heat shock proteins which dictates their influence on disease progression, as subcutaneous immunisation with recombinant mycobacterial Hsp65 induces atherosclerotic lesions in normcholesterolaemic rabbits,\(^3^5\) normal C57BL/6 mice fed a high fat diet,\(^3^6\) and low density lipoprotein receptor deficient mice,\(^3^7\) whereas mucosal (oral, nasal) administration (which deviates immune responses toward a Th2 (immunoregulatory) phenotype) decreases atherosclerosis in experimental mouse models.\(^3^8\)\(^-^4^1\) No studies have yet evaluated the therapeutic potential of “self” heat shock proteins.

**CONCLUSION**

It appears that the influence of circulating heat shock protein antibodies on cardiovascular disease depends on a number of factors in addition to their concentrations. The qualitative nature of these antibodies appears to be important, as might be their relation with circulating heat shock proteins. Further work is required in order to understand better the factors that drive the induction of heat shock protein antibodies and to clarify whether heat shock protein antibodies are active participants in the disease process. Changes in concentrations could be a consequence of as yet unidentified associations with the systemic inflammatory environment which is an inevitable feature of cardiovascular disease. Also required is a better understanding of the relation between heat shock protein antibodies and circulating heat shock proteins so that the influence of potentially anti-inflammatory soluble immune complexes can be fully evaluated. From these studies will come a better insight into the significance of heat shock proteins to cardiovascular disease and a better appreciation of the prognostic value of heat shock protein and heat shock protein antibody measurements.

**Authors’ affiliations**

A G Pockley, Division of Clinical Sciences (North), Northern General Hospital, Sheffield, UK

J Frostegård, Department of Medicine and Centre for Infectious Medicine, and Centre for Metabolism and Endocrinology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden

Competing interests statement: The authors have no interests which conflict or compete with this article.

**REFERENCES**


STAMPS IN CARDIOLOGY

Poster stamps

Another excellent poster stamp with a cardiovascular design was issued in Germany fifty years ago to publicise the Sport and Health Exposition held in Berlin from 20th June to 6th July 1952. The heart and arterial and venous circuits are depicted in the stylised discus thrower underscoring one of the common themes of poster stamps—sporting events and the Olympics.

M K Davies
A Hollman
Heat shock proteins in cardiovascular disease and the prognostic value of heat shock protein related measurements
A G Pockley and J Frostegård

Heart 2005 91: 1124-1126
doi: 10.1136/hrt.2004.059220

Updated information and services can be found at:
http://heart.bmj.com/content/91/9/1124

These include:

References
This article cites 39 articles, 21 of which you can access for free at:
http://heart.bmj.com/content/91/9/1124#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Drugs: cardiovascular system (8842)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/